MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Apabetalone

CAS No. : 1044870-39-4

MCE 站：Apabetalone

产品活性：Apabetalone (RVX-208) 是一种 BET 转录抑制剂，作用于 BD1 和 BD2，IC₅₀ 分别为 87 μM 和 0.51 μM。

研究领域：Epigenetics  |  Anti-infection

作用靶点：Epigenetic Reader Domain  |  HIV

In Vitro: Apabetalone (RVX-208) competes with binding of an acetylated histone peptide to tandem BD1 BD2 protein constructs of the four BET proteins, with IC₅₀s between 0.5 and 1.8 ?M. Apabetalone increases the production of ApoA-I in hepatocytes in vitro, which results in increased high density lipoprotein cholesterol (HDL-C). Apabetalone selectively binds to bromodomains of the BET (Bromodomain and Extra Terminal) family, competing for a site bound by the endogenous ligand, acetylated lysine, and that this accounts for its pharmacological activity. Apabetalone increases Apolipoprotein A-I (ApoA-I) production through an epigenetic mechanism and suggests that BET inhibition may be a promising new approach to the treatment of atherosclerosis. Apabetalone increases ApoA-I expression in liver cells.

In Vivo: In the atherosclerosis prophylactic treatment study design, mice are fed a Western diet concurrent with the treatment with 150 mg/kg/dose b.i.d. for 12 weeks. Mice are sacrificed at 12 weeks after treatment. There is a progressive increase in body weight in both the vehicle treated as well as the Apabetalone (RVX-208) treated groups. However, there is only an increase of 4 g (from 24 g to 28 g) body weight after 12 weeks on Western diet in the Apabetalone treated group whereas this increase is found to be 9 g (25 g-34 g) in the vehicle treated group. The significant decrease in body weight gain in Apabetalone treated mice is not due to decreased feed consumption, suggesting a positive attribute of the molecule. Plasma lipid measurements are done at 6 weeks and 12 weeks of treatment with either the vehicle or Apabetalone. Compared to the vehicle control animals, Apabetalone treated mice show significant increase (~200%) in the levels of HDL-C at 6 weeks of treatment, which is sustained until end of the study (12 weeks).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Antiviral Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Diabetes Related Compound Library  |  Anti-Blood Cancer Compound Library  |  Doxorubicin hydrochloride  |  Chloroquine  |  5-Fluorouracil  |  A-485  |  Curcumin  |  Valproic acid  |  (-)-Epigallocatechin Gallate  |  Birabresib  |  Shikonin  |  Ivermectin  |  Ebselen  |  Kaempferol  |  Flavopiridol  |  C646  |  Maraviroc  |  Hydroxyurea  |  Dimethyl fumarate  |  Baicalin  |  Probenecid  |  Ritonavir  |  Fasudil Hydrochloride  |  JQ-1 (carboxylic acid)  |  Lopinavir  |  Betulinic acid  |  Anacardic Acid  |  I-BET151  |  Lamivudine  |  Rolipram

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。